Clinical trials: Psychedelic Effects in Healthy Volunteers
Mood Disturbance, Mood Change
Mood and Cognitive Effects of Psilocybin in Healthy Participants
This study is seeking to find the optimal microdose or low dose of psilocybin (magic mushrooms) that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic…
- Conditions
- Mood Disturbance, Mood Change, Sleep Disturbance, Drug Effect
- Trial name
- MELO (NCT05252598)
- Testing
- Psilocybin, Inonotus Obliquus Whole Extract
- Volunteers
- healthy volunteers welcome
- Sponsor
- Optimi Health Corporation
Major Depressive Disorder
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive Disorder
The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
- Trial name
- NCT05385783
- Testing
- CYB003, Psychotherapy, Psychological Support
- Where
- 3 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Cybin IRL Limited
Healthy
Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects
Lysergic acid diethylamide (LSD) is a classic serotonergic psychedelic acting on the serotonin 5-HT2A receptor. LSD is used recreationally and in psychiatric research.
- Trial name
- SERT-LSD (NCT05175430)
- Testing
- Paroxetine, Lysergic Acid Diethylamide
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
QTc Interval, Pharmacokinetics
An Evaluation of Psilocybin's Effect on Cardiac Repolarization and the Effect of Food on Psilocybin's Pharmacokinetics
This study is comprised of two parts. The purpose of the first part of this study is to evaluate the effects of a supratherapeutic dose of psilocybin on cardiac repolarization.
- Trial name
- NCT05478278
- Testing
- Psilocybin, Moxifloxacin, Micro-Crystalline Cellulose
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Usona Institute
Psychedelic Effects in Healthy Volunteers
Investigation of Psychedelic Effects in Psychoactive Substances
The aim of this double-blind, placebo-controlled, within-subjects study is to determine whether other psychoactive substances can produce experiences akin to those seen with classic psychedelics.
- Trial name
- NCT06772753
- Testing
- Psilocybin, Ketamine, Dextromethorphan (DXM)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Healthy
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any…
- Trial name
- LBL (NCT05964647)
- Testing
- LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg)
- Where
- Switzerland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psychedelic Effects in Healthy Volunteers
Psilocybin Administration With 5-HT1a Blockade
The purpose of this study is to assess the effects of 5-HT1A receptor blockade on the acute subjective effects of psilocybin, as measured through subjective survey measures and acute electroencephalography (EEG).
- Trial name
- PsilBlock1 (NCT07565493)
- Testing
- Pindolol, Psilocybin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
5-methoxy-dimethyltryptamine (5-MeO-DMT)
Acute Effects of Intravenous 5-MeO-DMT in Healthy Participants
Participation in this study lasts approximately two weeks and includes three on-site study visits: a screening visit (approximately 2 hours), a study drug administration visit (approximately 4 hours), and a follow-up visit…
- Trial name
- MEOS (NCT07444788)
- Testing
- 0.2 mg/min 5-MeO-DMT, 0.4 mg/min 5-MeO-DMT, 0.6 mg/min 5-MeO-DMT
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Investigating the Importance of the Subjective Psychedelic Experience
Subjective Experience Following Psilocybin
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes.
- Trial name
- SEP-1 (NCT06768944)
- Testing
- Psilocybin high-dose, Psilocybin low-dose, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Disorders of Consciousness, Psychedelic Experiences
The Effects of Psilocybin on Shared Experience in Film Processing
The goal of this clinical trial is to learn whether certain methods of detecting awareness in vegetative or minimally conscious patients (using neuroimaging) are sensitive to the effects of psilocybin (a psychedelic drug).
- Trial name
- NCT06529939
- Testing
- Psilocybin
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Western University, Canada
Healthy Volunteers, Major Depressive Disorder
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
- Conditions
- Healthy Volunteers, Major Depressive Disorder, Depression
- Trial name
- NCT05434156
- Testing
- ELE-101
- Where
- 2 sites in United Kingdom
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Eleusis Therapeutics
Asperger's Disorder, Asperger Disorder
QAIAx (AIhealth4U) - AI Smart Health Cities: Microcity Enclave Program (Quantum AI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360)
BRIEF SUMMARY A. "What is the purpose of this study?" BACKGROUND. The QAIAx clinical trial (Quantum AI/AGI Public Health Agency), known operationally as the "AI City Hall Project," represents a landmark intergovernmental research…
- Conditions
- Asperger's Disorder, Asperger Disorder, Autism Disorder, Autism
- Trial name
- QAIAx (NCT07661823)
- Testing
- AI City Hall Project (AIhealth4u - Public Health Central), AI City Hall Project (QAIAx Microcity A - AI Public Health Central)
- Where
- United States
- Volunteers
- 1,000,000 people, healthy volunteers welcome
- Sponsor
- Veterans Recovery Network Inc.